The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales ...

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...

This is the second SOD application center that Merck has established in Asia to meet the region’s high demand.

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Jefferies analyst Brian Balchin maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €180.00. The company’s shares closed yesterday at €157.19.

Deutsche Bank (ETR:DBKGn) has adjusted its price target for Merck KGaA (MRK: GR) (OTC: MKGAF), reducing it to €180.00 from the previous €188.00, while retaining a Buy rating on the stock. The ...

Deutsche Bank has adjusted its price target for Merck KGaA (MRK: GR) (OTC: MKGAF), reducing it to €180.00 from the previous €188.00, while retaining a Buy rating on the stock. The modification ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...